April 17, 2018

Immunocellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Immuno-Oncology Research

Company Successfully Transfers T-Cell Receptor Genetic Material into Human Hematopoietic Stem Cells ImmunoCellular Therapeutics, Ltd., a Los Angeles-based clinical stage immuno-oncology company, has achieved an important milestone toward initiating pre-clinical trials of its Stem-to-T-Cell approach to cancer therapy.   ImmunoCellular Therapeutics has verified the successful transfer of selected T-cell receptor […]
April 17, 2018

Immix Biopharma Welcomes Two Oncologists to Medical Advisory Board

Immix Therapies Enhance Apoptotic Activity of FDA-Approved Agents by 5X and Catalyze Total Shift in Tumor Micro-Environment Immix Biopharma, Inc., a Los Angeles-based clinical-stage biopharmeceutical company developing therapies for high unmet medical needs, has recently appointed two world-reknowned oncologists to its Medical Advisory Board.  Dr. George Sledge is Professor and […]
December 14, 2017

CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study

CEL-SCI Corporation recently announced that no further patient enrollment is required in the pivotal Phase 3 head and neck cancer study of its investigational immunotherapy, Multikine. The accrual and treatment phases of this Phase 3 study are complete. 928 patients are enrolled in the study, and are being followed-up as required […]
December 2, 2017

TapImmune Completes Patient Enrollment in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer

TapImmune Inc., a Florida-based leading clinical-stage immuno-oncology company recently announced that it has enrolled the final patient in a randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV200 for treating triple-negative breast cancer (TNBC). This study is designed to help determine the optimal vaccine dose and regimen […]
November 21, 2017

Gismo Therapeutics Inc. Receives Two Grants to Develop Novel Therapeutics for Parkinson’s Disease

Gismo Therapeutics Inc. has been awarded two grants to continue their development of therapies to treat Parkinson’s Disease. A $384,000 SBIR grant entitled “Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinson’s Therapeutic” was awarded by the National Institute of Neurological Disorders and Stroke (NINDS) – NIH. In addition to this, Gismo Therapeutics […]
November 21, 2017

Excision BioTherapeutics Secures $10 Million in Seed Funding Led by ARTIS Ventures

Excision BioTherapeutics, a life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life-threatening disease caused by neurotropic viruses, recently announced it has completed a $10 million seed round of financing, led by ARTIS Ventures. The investment will enable the company to […]
November 21, 2017

Dance Biopharm Announces Buyback of Dance-501 Asia License from Harmony Plus Holdings

Dance Biopharm Holdings, Inc., a privately-held San Francisco-based biotechnology company focused on the development of Dance-501, a proprietary ‘soft-mist’ inhaled insulin product to treat diabetes, recently announced the purchase of Harmony Biopharm Limited, the holder of its Dance-501 Asia license, from Harmony Plus Holdings Limited, an affiliate of Harmony Asset […]
November 21, 2017

Soligenix to Present at the 2017 Biotech and Money Showcase Conference

Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, recently announced that its President and Chief Executive Officer, Christopher J. Schaber, PhD, is to deliver a corporate presentation at the 2017 Biotech & Money […]
October 27, 2017

Antinitus featured in 7 News Sydney

Antinitus, a patch designed to reduce the discomfort of tinnitus created by Swedish company Sensori AB, was recently featured on 7 News Sydney. The video follows the progress of three people suffering from tinnitus, and their experience with the Antinitus patch. Tinnitus is classified as an unwanted noise which can […]
August 31, 2017

TapImmune Amends Patient Inclusion Criteria for Phase 2 Clinical Trial

TapImmune (TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women’s cancers has announced that it has amended the patient inclusion criteria for its Phase 2 clinical trial of their T-cell therapeutic peptide vaccine TPIV200 to focus on women with Stage III and IV ovarian cancer who […]
August 31, 2017

ProMIS Neurosciences Completes Second Closing of Private Placement

ProMIS Neurosciences Inc. has announced that it has completed the final closing on a non-brokered private placement basis of its previously announced private placement of units of ProMIS Neurosciences for gross proceeds of $1,070,000. In two closings, the ProMIS has raised aggregate gross proceeds of approximately $4,800,000. Regarding this announcement, […]
August 24, 2017

Dorsey Represents Mayo Clinic’s Venture Applying AI in Drug Development

Dorsey client Mayo Clinic and Cambridge, Massachusetts-based nference recently announced the formation of Qrativ. Qrativ will combine nference’s artificial intelligence (AI) knowledge synthesis platform with Mayo Clinic’s medical expertise and clinical data to discover and develop treatments for diseases with unmet medical need. This effort is being boosted by an […]
August 24, 2017

Soligenix Initiates Phase 3 Trial of Dusquetide for Oral Mucositis in Head & Neck Cancer Patients

Soligenix’s self-described “DOM–INNATE” study has initiated patient enrollment. The late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that patient enrollment has been opened for its Phase 3, multinational, randomized, double-blind, placebo-controlled study evaluating SGX942 (dusquetide) as a […]
August 24, 2017

Avant Diagnostics Announces Confirmatory Clinical Utility Data for Theralink in Pancreatic Cancer

Avant Diagnostics, Inc. (‘Avant’) (OTC: AVDX), an oncology-focused healthcare technology company commercializing the proprietary Theralink proteomic biomarker platform announced positive clinical utility data, the confirmation of the clinical utility of the Theralink Pancreatic Cancer assay in an expanded 60 patient data study in distinguishing patients that will experience a 5-year […]
August 24, 2017

Circadiance Partners with the VGM Group

Circadiance, a company widely-known as a pioneer in respiratory therapy medical devices, announced a partnership with The VGM Group to offer their innovative respiratory products to independent Home Medical Equipment providers in communities across America. Circadiance’s innovative sleep and monitoring products specialize in positive airway pressure, noninvasive ventilation and apnea […]
August 2, 2017

Histogen’s Growth Factor Technology to be Marketed as part of Allergan Skin Care Line

Histogen, Inc., a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, today announced that its proprietary multipotent cell conditioned media will be marketed by leading global biopharmaceutical company Allergan within its recently-acquired Regenica® Advanced Rejuvenation System. The Multipotent Resignaling Complex (MRCxTM) within Regenica is made […]
July 31, 2017

TapImmune Enrolls 50% in Phase 2 Triple Negative Breast Cancer Study

TapImmune Inc, a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women’s cancers, announced that it has enrolled 50% (40/80) of the patients in its randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV 200 for treating triple-negative breast cancer (TNBC). The four-arm study is […]
July 31, 2017

Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine

Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has exercised an option for the […]
July 31, 2017

Enterin Discovers Link Between Upper GI Infections and Parkinson’s Disease

Michael Zasloff, MD, Ph.D., Professor of Surgery and Pediatrics at Georgetown University School of Medicine, and Founder, Chairman and CEO of Enterin Inc. was the senior author of a study that has helped clarify the function of alpha-Synuclein (αS), the protein implicated in Parkinson’s disease (PD) and other neurodegenerative diseases. […]
July 31, 2017

ProMIS Neurosciences’ Research Agreement with U. British Columbia Receives $262k Matching Grant from Canadian Institutes of Health Research

ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that the company’s sponsored research agreement with the University of British Columbia (UBC) has received a matching Industry Partnered Grant from the Canadian Institutes of Health Research (CIHR). The peer-reviewed […]